Introduction
The hexanucleotide (G
4C
2) repeat expansion in the chromosome 9 open reading frame 72 (
C9ORF72) gene is the most common genetic cause of FTD and ALS [
12,
33]. FTD is characterized by the degeneration of the frontal and temporal parts of the brain, leading to abnormalities in behavior, language and personality [
49]. ALS affects motor neurons in the brain and spinal cord, leading to loss of motor function, muscle weakness, breathing problems and eventually paralysis [
52]. Clinical, pathological and genetic factors connect FTD and ALS, and in families often patients present with symptoms of both disorders [
4]. The discovery of the
C9ORF72 hexanucleotide repeat expansion confirmed the genetic overlap between FTD and ALS, collectively referred to as C9FTD/ALS. Pathologically, both diseases present with inclusions of autophagy protein p62/sequestosome 1 (p62) and inclusions of phosphorylated 43 kDa TAR DNA-binding protein (pTDP-43), of which the latter is predominantly found in areas that are known to display substantial neurodegeneration [
24,
44].
The possible pathological mechanisms by which the
C9ORF72 repeat expansion can lead to FTD and ALS are: 1) hypermethylation of the repeat expansion and the CpG promoter region of the
C9ORF72 gene leading to haploinsufficiency [
5,
43], 2) retention of repeat containing intron 1 in mRNAs causing RNA foci to appear in both nucleus and cytoplasm that sequester RNA-binding proteins [
11,
27] or 3) the production of dipeptide repeats (DPR) by unconventional repeat-associated non-AUG (RAN) translation of the repeat [
2,
18,
31]. These DPRs are produced from both sense and antisense transcripts resulting in 5 possibly toxic peptides (poly-GA, −GP, −GR, −PR and -PA) and are found as inclusions in post-mortem brain material of
C9ORF72 carriers [
28,
38].
How these three mechanisms – alone or in combination – cause neurodegeneration is currently under investigation. Several studies have indicated that especially the DPRs are toxic in both cell culture and in vivo models, with the arginine-containing poly-GR and -PR DPRs being the most detrimental [
3,
30,
47]. And poly-GR has been associated with neurodegeneration in human post-mortem brain sections [
35,
36]. DPRs seem to cause various types of stress to the cell, including ER-stress, mitochondrial stress and nucleolar stress [
3]. They can disturb the formation of membrane-less organelles, including RNA granules, nucleoli, spliceosomes and the nuclear pore complex (NPC) and facilitate the formation of stress granules [
26]. Furthermore, nucleocytoplasmic transport and autophagy defects have been reported [
40,
53,
56]. In addition to the list of disturbed pathways found in model systems of C9FTD/ALS, there have also been a substantial number of proteins found to interact, bind or aggregate with repeat-containing RNA or DPRs [
21,
48]. Currently, the primary affected pathways involved in the pathogeneses of C9FTD/ALS are under debate [
3,
17,
19]. Constituents of inclusions in human C9FTD/ALS brain material might provide a tool to identify key players in neurodegeneration.
Here, we tested a set of proteins implicated in aberrant pathways in
C9ORF72 disease models for their presence in pathology or abnormal localization in post-mortem human C9FTD/ALS brain sections. We selected Ran-GAP for its implication in nucleocytoplasmic transport defects [
54], ADARB2 for its role in RNA binding and editing [
13] and HR23B for its dual function in both DNA repair and the UPS [
51]. FMRP and Pur-alpha were selected for their binding to
C9ORF72 mRNA, their localization in stress granules and their rescue effect in multiple
C9ORF72 models [
34]. Surprisingly, we found only HR23B protein to be a constituent of inclusions observed in C9FTD/ALS cases. In this report, we describe HR23B distribution and its co-localization with known
C9ORF72 pathological hallmarks (DPRs, p62 and pTDP-43). Furthermore, we analyze HR23B function in DNA damage repair, the ubiquitin-proteasome system and ER-associated degradation. Disturbances of these pathways may contribute to the disease onset and/or progression of C9FTD/ALS.
Materials and methods
Five
C9ORF72 FTD, two
GRN FTD, two
MAPT FTD, three sporadic ALS and three non-demented control human brain sections were provided by the Dutch Brain Bank.
C9ORF72 ALS brain material of two patients was collected post-mortem at the department of Neuropathology of Amsterdam UMC, University of Amsterdam, according to local legal and ethical regulations. Patients or relatives gave informed consent for autopsy and use of brain tissue for research purposes. Information about our patient cohort can be found in Table
1. Human fibroblasts lines were provided by the cell repository of the department of clinical genetics. All participants gave written informed consent for all obtained materials. The study was approved by the Medical and Ethical Review Committee of the Erasmus Medical Center. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Table 1
Patient characteristics
1 | bvFTD | FTD | C9ORF72 | 51,8 | 8,7 | Male | 960 g |
2 | bvFTD | FTD | C9ORF72 | 55,8 | 9,1 | Male | 1184 g |
3 | bvFTD | FTD and ALS | C9ORF72 | 66,4 | 8,1 | Female | 1060 g |
4 | bvFTD | ALS and dementia | C9ORF72 | 63,2 | 6,8 | Female | 958 g |
5 | bvFTD | FTD and ALS | C9ORF72 | 55,2 | 9,5 | Male | 1075 g |
6 | FTD | N/A | Progranulin (Gln200X) | 60,6 | 5,5 | Female | 894 g |
7 | FTD | FTD | Progranulin (Ser82ValfsX174) | 47,4 | 4,3 | Female | unknown |
8 | FTD | FTD | MAPT (G272 V) | 42,6 | 8,4 | Male | 962 g |
9 | FTD | FTD | MAPT (P301L) | 51,1 | 9,7 | Male | 887 g |
10 | ALS | N/A | unknown | 70 | 1 | Male | 1428 g |
11 | ALS | N/A | unknown | 65 | 2,2 | Female | 1125 g |
12 | ALS | N/A | unknown | 75 | 1,1 | Male | 1255 g |
13 | ALS | N/A | C9ORF72 | 60 | 4,4 | Female | 1390 g |
14 | ALS | N/A | C9ORF72 | 66 | 3,5 | Male | 1275 g |
15 | ALS | N/A | C9ORF72 | 71 | 2,4 | Female | 1080 g |
16 | Non-demented | N/A | unknown | N/A | N/A | Female | 1080 g |
17 | Non-demented | N/A | unknown | N/A | N/A | Male | 1215 g |
18 | Non-demented | N/A | unknown | N/A | N/A | Female | 1139 g |
Immunohistochemistry on human brain sections
Human brain sections (6 μm) were deparaffinized in xylene and rehydrated (100%–96%-90%–80%-70%–50% EtOH serie). Antigen retrieval was done in 0.01 M sodium citrate, pH 6.0 using pressure cooker treatment. Endogenous peroxidase activity was blocked with 0.6% H
2O
2 and 1,25% sodium azide in 0.1 M PBS. Immunostaining was performed overnight at 4 °C in PSB block buffer (0.1 M PBS/0.5%protifar/0.15%glycine). Antibodies used in this study are listed in Additional file
1: Table S3, including concentration and brand/catalogue number. Antigen-antibody complexes were visualized by incubation with DAB substrate (DAKO) after incubation with Brightvision poly-HRP-linker (Immunologic) or anti-mouse/rabbit HRP (DAKO). Slides were counterstained with Mayer’s haematoxylin and mounted with Entellan (Merck Millipore International). The slides were then left to dry in the fume hood for an hour and thereafter put in an 37 °C incubater overnight. Pictures were taken by using an Olympus BX40 microscope (Olympus).
Immunofluorescence staining on human brain sections
Human brain sections were treated as described above. After incubation with the primary antibody, sections were washed with PBS block buffer (1xPBS/0.5%protifar/0.15%glycine) and incubated with secondary anti-mouse/rabbit Cy2/3 linked antibodies (Jackson). To remove background staining, a 10 min incubation with Sudan Black (Sigma, 0.1 g in 100 ml 70% ethanol, filtered) was done. To visualize nuclei, slides were incubated for 10 min with Hoechst 33342(Invitrogen). Slides were mounted with ProLongGold (Invitrogen) and kept at 4 °C until imaging at a Zeiss LSM700 Confocal microscope.
Assessment of neurodegeneration and protein pathology
For the neuropathological assessment we used brain sections from 5
C9ORF72 FTD cases (see Table
1). Five different brain regions (frontal cortex, temporal cortex, motor cortex, hippocampus and cerebellum) per patient were semi-quantified on neurodegeneration and pathological score of p62, pTDP-43 and HR23B (Additional file
2: Table S1). Counting was not performed in a blinded fashion. Neurodegeneration was assessed on haematoxylin and eosin (HE) sections and graded as absent (0), mild (1), moderate (2) or severe (3) based on the presence of neuronal loss. The neurodegenerative score from the pathological report was also taken into account. Pathological scores were rated as (0) if completely absent, rare (1) if only a few could be found one brain section, occasional (2) if they not present in every microscopic field, moderate (3) if at least a few examples were present in most microscopic fields, and numerous (4) when many were present in every microscopic field [
28]. We reported the overall number of immunoreactive inclusions (total score) as well as the number of neuronal cytoplasmic inclusions (NCI), neuronal intranuclear inclusions (NII) and dystrophic neurites (DN) (Additional file
2: Table S1). Total scores were assessed independent from NCI, NII and DN scores and represent an impression of the global load of pathology and the number of inclusions using the same grading system as described above. Quantification of co-localization of HR23B with DPRs, p62 and pTDP-43 was not performed in a blinded fashion.
Human fibroblast lines from 4 C9ORF72 carriers (13E634, 13E659, 17E0225, 17E0278) and 4 controls (81E253, 86E1375, 06E0717 and 99E0774) were obtained from the cell repository of the department of clinical genetics and the XP25RO fibroblast line was provided by the department of molecular genetics. Fibroblasts were cultured in DMEM medium (Gibco) with 10% fetal calf serum, 1% penicillin/streptavidin and 1% non-essential amino acids. To determine UV-sensitivity, human fibroblasts were seeded in triplicate in 10 cm plates (Greiner Bio-one) in a density of 2000 cells/plate. After 24 h, cells were treated with increasing doses of UV-C (254 nm UV-C lamp, Philips). After 5–7 days, colonies were fixed with 0.1% w/v Coomassie Blue (Bio-Rad) in a 50% Methanol, 10% Acetic Acid solution. Colonies were counted with the integrated colony counter GelCount (Oxford Optronix). Counting was performed automatically with the same settings for each fibroblast cell line, but not in a blinded fashion.
Immunofluorescence on human fibroblasts
To determine DNA damage recruitment of NER proteins, human fibroblasts were seeded on coverslips and after 1 week in culture irradiated with 60 J/m2 (254 nm UVC lamp, Philips) through an 8 μm microporous filter (Millipore) to induce sub-nuclear local DNA damage. Cells were fixed after 30 min with 2% paraformaldehyde and permeabilized with 0.1% Triton X-100 for 20 min. Next, cells were incubated with fresh 0.07 M NaOH in PBS for 5 min to denature DNA and enable CPD staining. Cells were then washed with PBS containing 0.15% glycine and 0.5% BSA and incubated with primary antibodies (see Additional file
1: Table S3) overnight at 4 °C. The next day, cells were washed with 0.1% Triton X-100 and incubated with Alexa Fluor conjugated secondary antibodies (488, 555 and 633; Invitrogen) for 1 h at RT. Coverslips were mounted using ProLongGold with DAPI (Invitrogen) and imaged using a Zeiss LSM700 microscope.
Unscheduled DNA synthesis (UDS)
To measure NER capacity, human fibroblasts were grown on coverslips for 1 week in culture and irradiated with 16 J/m2 UV-C. After irradiation, cells were incubated for 1 h in UDS medium (F10, 1% PS, 10% dialyzed serum) with 2% HEPES and 1% 5-ethynyl-2′-deoxyuridine (EdU, Invitrogen). After 1 h, medium was changed to normal DMEM medium (10% FCS, 1% NEAA, 1% PS) for 10 min. Next, cells were fixed in 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. Blocking was done using 1.5% BSA in PBS for 30 min. EdU incorporation was visualized by incubating cells for 1 h at room temperature with Click-it reaction cocktail containing Atto 594 Azide (60 μM, Atto Tec.), Tris-HCl (50 mM, pH 7.6), CuSO4*5H2O (4 mM, Sigma) and ascorbic acid (10 mM, Sigma). After the Click-it reaction, cells were washed with 0.1% Triton X-100, incubated with Hoechst 33342 (Invitrogen) for 10 min and mounted with ProLongGold (Invitrogen). Images were acquired using a Zeiss LSM700 microscope. UDS levels were quantified by measuring the total nuclear fluorescence intensities (in at least 50 cells per experiment) with FIJI image analysis software. Intensity levels were averaged and normalized to the fluorescence levels in unirradiated cells. Quantification of intensity levels was done automatically with FIJI but was not performed in a blinded fashion.
Discussion
In the present study, we characterize HR23B pathology distribution and its co-localization pattern with pathological hallmarks. To our knowledge, we are the first to show that HR23B co-localizes with pTDP-43 pathology in brain tissue of C9FTD patients. We could also demonstrate HR23B pathology in C9ALS and sporadic ALS. HR23B pathology has been described before in HD, SCA3, SCA7, FXTAS and PD [
6]. HR23B pathology was also present in both
C9ORF72 and
GRN FTD cases, but not in
MAPT FTD cases, in contrast to a previous report of HR23B pathology described for FTDP-17 (FTD with parkinsonism with Pick bodies consisting of tau protein) [
6]. Also Alzheimer’s disease (AD) brain material did not show HR23B pathology [
6]. Why AD and some FTLD-tau patients are an exception and do not present with HR23B pathology is unclear and requires further investigation. It should be noted that our study cohort was rather small (see Table
1), which might explain why we could not confirm HR23B pathology in
MAPT FTD cases. Next to HR23B, HR23A inclusions have been reported in FXTAS and in C9FTD post-mortem brain tissue [
6,
55]. In general, HR23 pathology seems to be widespread among neurodegenerative diseases, which underscores its relevance in a common disease pathogenesis of these disorders.
In our semi-quantitative co-localization studies, we found HR23B to be co-localized predominantly with p62, followed by pTDP-43 and poly-GA. HR23B inclusions were nearly always negative for the other DPRs. Overexpression of poly-GA in mouse models is enough to sequester HR23B [
37,
55] and in a co-immunoprecipitation experiment of lysates from cells expressing GFP-tagged poly-GP, −GR and -GA, only poly-GA was found to bind HR23B [
55]. This could also be a stochastic event, given the fact that poly-GA inclusions are the most abundant DPR in C9FTD/ALS brains [
28]. It could also be caused by the aggregation-prone nature of the poly-GA peptide itself [
9], causing HR23B to bind easier or faster to poly-GA peptides than other DPRs. Binding of HR23B to DPRs also differs between brain areas; in the frontal cortex, only 6.6% of HR23B inclusions were poly-GA positive, while this increased to 60.6% in the hippocampus dentate gyrus. The same is true for poly-GP and -GR; co-localization with HR23B increased 5- to 10-fold between frontal cortex and hippocampus, although it remained low (1–10%). Subtypes of neurons may differ in their vulnerability for DPRs or there might be differences in the expression level and availability of HR23B and/or its binding partners between frontal cortex and hippocampus dentate gyrus. Levels of HR23B can influence aggregation of poly-GA and toxicity of mutant TDP-43 and mutant SOD1 [
23,
55]. Overexpression of HR23B protected for the formation of poly-GA inclusions in mouse primary neuronal cultures [
55]. In contrast, loss of HR23B seems to protect against motor neuron disease by enhancing mutant protein clearance [
23]. Levels of HR23B seem to have opposite effects on aggregation, clearance and solubility of several proteins, which could result in differences in aggregation and co-localization patterns observed between different brain areas.
HR23B can directly bind the proteasome and ataxin-3, a deubiquitinase enzyme that binds ubiquitinated proteins and can also bind to the proteasome [
14,
46]. Even though HR23B and proteasome subunits are sequestered into intranuclear inclusions of ataxin-3 in SCA3 patients brain tissue [
6,
39], ataxin-3 and 20S do not show an aberrant localization in C9FTD patients post-mortem brain tissue. HR23B can also bind PNGase, a deglycosylation hydrolase involved in ERAD of misfolded glycoproteins. The affinity of PNGase for the proteasome is HR23B-dependent, which makes HR23B essential for the shuttling of misfolded proteins to the proteasome [
25]. If HR23B is sequestrated into inclusions and becomes unavailable for PNGase, this might cause loss of initiation of ERAD. This is in line with our observation that a substantial number of neurons of C9FTD/ALS patients show less abundant NGly1 staining. Many FTD-causing mutations are associated with protein degradation pathways [
20]. In addition, mutations in
NGLY1, the gene encoding PNGase, are linked to motor impairment, intellectual disability, and neuropathy in humans [
8].
HR23B is well known for its role in global genome nucleotide excision repair (GG-NER) and genetic polymorphisms in
RAD23B are modifiers of laryngeal cancer risk in human [
1]. The DNA damage response can be induced by the
C9ORF72 repeat expansion [
15] and elevated levels of R-loops (DNA-RNA hybrids), double strand breaks and ATM-mediated DNA repair signaling defects have been described before in rat neurons, human cells and C9ALS spinal cord tissue [
15,
45]. Furthermore, ALS and
C9ORF72 repeat carriers have an increased risk for melanoma [
16,
42], suggesting they may have an reduced response to DNA damage. XPC, the binding partner of HR23B in NER, was found in inclusions in a poly-GA mouse model of C9FTD/ALS [
55]. Nonetheless, we could not find XPC pathology in our human brain sections nor deficits in the NER pathway in
C9ORF72 patient fibroblasts, even though
C9ORF72 patient fibroblasts seem to be more sensitive for UV-C damage than healthy control fibroblasts. Why we do not find a clear impairment of NER in our study is unknown. Species-specific factors, overexpression of poly-GA in the mouse model or difference between fibroblasts and neurons might explain a part of the absence of an effect. In addition, it could be possible that HR23A takes over the DNA repair function of HR23B when the latter is sequestered or dysfunctional. This has been demonstrated in
mHr23b knockout (KO) mice that show no impairment in NER [
51]. Still,
mHr23b KO mice display impaired embryonic development, retarded growth and facial dysmorphologies that are not observed in mouse models deficient in other NER genes [
51], which suggests a second function of HR23B. Although HR23A and HR23B have similar functions in DNA repair, they form distinct interactions with various cellular factors, including proteasomes, multi-ubiquitinated proteins and stress-related factors [
10].
Here, we set out to validate the aggregation of several proteins that have been described to mis-localize or bind RNA foci in C9FTD/ALS. Strikingly, we could not reproduce earlier published pathology for Ran-GAP, ADARB2, Pur-alpha and FMRP. The differences observed between our study and previous publications can be explained by multiple factors. First of all, we used post-mortem brain material that only presents the end-stage of the disease, so changes in localization of proteins in early stages of the disease can be missed. Also, the number of cells presenting with stress granules varies a lot between subjects and might be attributed to autolytic processes during human brain preservation, which can make it hard to detect subtle differences. Secondly, this study focused on FTD rather than ALS. This could especially be important for ADARB2, as one of the targets of ADAR proteins is the Q/R site of the GluR2 AMPA receptor [
22]. Changes in ADARB2 localization could therefore mostly affect ALS cases and may be missed in our FTD cohort. Thirdly, pathology observed in cell culture and in vivo models could be due to overexpression of
C9ORF72 RNA or DPRs in these models. Changes in patient neurons with endogenous expression can be more subtle but still act disturbing over time. Most model systems used so far do not include haploinsufficiency, which can be a modifying factor for cellular toxicity as well [
41]. Finally, effects might be missed due to our small cohort. For example, differences in oddly-shaped nuclei in the Ran-GAP staining might only become evident when quantifying large number of cells. However, Saberi et al. also were unable to confirm Ran-GAP pathology [
35], which strengthens our findings and illustrates the need for validation studies in biomedical research. Even though we did not observe any pathology of Ran-GAP, ADARB2, FMRP and Pur-alpha, their levels could still have a modifying effect on disease progression of FTD, as has been shown in iPSC-derived neurons and Drosophila models [
7,
13,
50,
54].